Xinhuosu (nesiritide)
/ China Medical System
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 31, 2026
Study on the efficacy and safety of recombinant human brain natriuretic peptide (Xinhuosu) in the treatment of acute heart failure patients (randomized controlled trial) Study on the efficacy and safety of recombinant human brain natriuretic peptide (Xinhuosu) in the treatment of acute heart failure patients (randomized controlled trial)
(ChiCTR)
- P=N/A | N=514 | Not yet recruiting | Sponsor: Fuwai Hospital, Chinese Academy of Medical Sciences; Fuwai Hospital, Chinese Academy of Medical Sciences
New trial • Cardiovascular • Congestive Heart Failure • Heart Failure
January 31, 2026
A prospective, randomized, controlled clinical study on the treatment of patients with decompensated chronic heart failure and diuretic resistance with recombinant human brain natriuretic peptide
(ChiCTR)
- P=N/A | N=100 | Not yet recruiting | Sponsor: Tianjin Chest Hospital; Tianjin Chest Hospital
New trial • Cardiovascular • Congestive Heart Failure • Heart Failure
October 31, 2025
A single-center, prospective controlled study on the efficacy of loose volume combined with recombinant human brain natriuretic peptide (Xinhuosu) in patients with acute exacerbation of chronic heart failure.
(ChiCTR)
- P=N/A | N=104 | Not yet recruiting | Sponsor: Ordos Central Hospital; Ordos Central Hospital
New trial • Cardiovascular • Congestive Heart Failure • Heart Failure
1 to 3
Of
3
Go to page
1